EDAN(SZ:300206) 仪器信息网·2025-10-21 09:09Core Viewpoint - The establishment of a localized manufacturing center in San Diego by Shenzhen Lifang Precision Instrument Co., Ltd. marks a significant step towards achieving full localization of its medical instrument products, enhancing its competitiveness in the North American market [2][3]. Group 1: Localization and Market Strategy - The new manufacturing center spans approximately 1,940 square meters and has received MDSAP certification, indicating compliance with international regulatory standards [2]. - This facility will enable Lifang to shorten service response times for North American clients and provide stable instrument supply and localized technical support, particularly in high-end monitoring and diagnostic equipment [2][3]. - The MDSAP certification covers major markets including the US, Canada, Australia, Japan, and the EU, which strengthens Lifang's competitive position in North America and lays the groundwork for future expansion into Asian and European high-end medical instrument markets [2][3]. Group 2: Implications for Procurement and Manufacturing - For scientific instrument purchasers, Lifang's localization means shorter delivery times, lower transportation costs, and more flexible customization services [3]. - Instrument manufacturers are encouraged to accelerate technological iterations to adapt to the restructuring of global supply chains, potentially leading to a new model of "local production + global collaboration" in the medical device industry [3]. Group 3: Company Overview and R&D Investment - Lifang focuses on innovation and clinical proximity, covering six major business segments: patient monitoring, ECG diagnosis, women's health, in vitro diagnostics, ultrasound imaging, and smart health [4]. - In 2024, the company's R&D investment is projected to account for 18.55% of its revenue, with cumulative R&D spending exceeding 2.71 billion since its listing in 2011, establishing strong partnerships with over 50,000 medical institutions [4].